Richard Roberts (pharmaceutical executive)

New Healthcare & Life Sciences Communications Firm, ReadHealthy Communications, Announces Company Launch

Retrieved on: 
Monday, October 9, 2023
Ophthalmology, Health, Corporate title, MS, Human, Boston University, Kendall Hunt Publishing Company, Communication, Empathy, Cardiology, Neurology, Writing, Health communication, Medication, Data, Mental health, Vision disorder, Richard Roberts (pharmaceutical executive), Marketing, Publication, Optic nerve hypoplasia, William Paterson University, Racism, Disability, PR, Journalism, Patient, Management, Science

LIVINGSTON,N.J., Oct. 9, 2023 /PRNewswire-PRWeb/ -- Jennifer Ringler, the firm's founder & CEO, is a former journalist and member of the blind and visually impaired community –

Key Points: 
  • ReadHealthy Communications' founder & CEO, Jennifer Ringler, MS, is an experienced healthcare communicator and former journalist who was born with a rare vision disorder, optic nerve hypoplasia.
  • ReadHealthy Communications, a public relations, marketing, and corporate communications firm serving clients in pharma, biotech, med tech, health tech, and other areas of healthcare, announced today its official company launch.
  • "I learned so much and helped tell so many important stories in healthcare while working at other communications and PR agencies for the past decade," said Jennifer Ringler, MS, ReadHealthy Communications' founder & CEO.
  • Jennifer has been published in Pharmaceutical Executive, Life Science Leader, Chief Healthcare Executive, PRNews, and many other industry blogs and publications.

Renowned Physician-Pharmacist Dr. Anita Gupta joins Erez Capital, Bringing Healthcare Innovation Expertise on Board.

Retrieved on: 
Thursday, July 27, 2023
HuffPost, US Food Sovereignty Alliance, Goldman, Naloxone, The New York Times, National academy, National Academies of Sciences, Engineering, and Medicine, Distinguished Fellow of the British Computer Society, U.S. Venture Partners, CNN, MSNBC, Goldman Sachs, Business Leaders for Michigan, Publication, Drug, Capital, Harvard Business School, Pain management, FDA, Woman, Princeton University, Fentanyl, Industry Dive, Food, Anesthesiology, Richard Roberts (pharmaceutical executive), Medical device, The Washington Post, Engineering

Dr. Gupta, a global leader in healthcare innovation, is renowned for her ground-breaking contributions to the medical field and her exceptional expertise in anesthesiology and pain management.

Key Points: 
  • Dr. Gupta, a global leader in healthcare innovation, is renowned for her ground-breaking contributions to the medical field and her exceptional expertise in anesthesiology and pain management.
  • With an illustrious career and a portfolio of remarkable accomplishments, Dr. Anita Gupta has made a significant impact on healthcare innovation and patient advocacy.
  • Throughout her career, Dr. Gupta's dedication to healthcare innovation has led her to spearhead pioneering initiatives in the United States.
  • Dr. Anita Gupta's addition to Erez Capital reinforces the firm's commitment to collaborating with top-tier professionals and industry leaders to foster innovation and make a lasting impact in the healthcare sector.

Pharmaceutical Executive® opens call for entries for third annual APEX Awards

Retrieved on: 
Friday, April 28, 2023
Communication, Marketing, Greenwich Savings Bank Building, Medication, Food and Drug Administration, Nursing, Richard Roberts (pharmaceutical executive), Knowledge, FDA, Food, Disease, Pharmaceutical industry

“I am excited to announce the commencement of the entry process for the third annual Pharmaceutical Executive APEX Awards program,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences®, parent company of Pharmaceutical Executive.

Key Points: 
  • “I am excited to announce the commencement of the entry process for the third annual Pharmaceutical Executive APEX Awards program,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences®, parent company of Pharmaceutical Executive.
  • “This program honors pioneering and innovative work in the pharmaceutical sector and is judged by the health care professionals who truly understand its value.
  • The evaluation of entries will be conducted by an esteemed panel of health care professionals located throughout the United States.
  • Last year’s APEX Awards saw an impressive number of entries, and a huge congratulations to all our 2022 winners who were honored at a live show in October.

The Pharma Mini MBA Training Course: Featuring Business School Pharmaceutical Case Studies

Retrieved on: 
Friday, April 21, 2023
Pharma, Ministry of National Health Services, Regulation and Coordination, University, National Health Service, Predicted impact of Brexit, PwC, RQA, Policy, Medication, Health, Health Economics, Euromed, HTA, Hoechst AG, Research, Patient, Doctor of Philosophy, Pharmaceutical Price Regulation Scheme, Bachelor of Science, Economics, Oguz, Integrity, International Drug Policy Consortium, Master of Science, Clinical research, Richard Roberts (pharmaceutical executive), Cancer Drugs Fund, Pharmacy school, School, Consumer, Phoenix International Holdings, Health technology assessment, Fine chemical, Pharmaceutical industry, Pharmacy

BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.

Key Points: 
  • BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.
  • This follows 7 years at a specialist economic consulting firm working in a small dedicated health and pharmaceutical team.
  • She regularly writes on hot topics affecting the industry for Pharmaceutical Executive, Pharmaphorum and EyeforPharma and has also written for PharmaTimes, and Pharma Pricing and Reimbursement.
  • Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff.

The Pharma Mini MBA Training Course: Accelerated Management Programme for Pharmaceutical Industry Employees - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 19, 2023
Health, Pharmaceutical, Pharma, Ministry of National Health Services, Regulation and Coordination, University, National Health Service, Predicted impact of Brexit, PwC, RQA, Policy, Medication, Health Economics, Euromed, HTA, Hoechst AG, Research, Patient, Doctor of Philosophy, Pharmaceutical Price Regulation Scheme, Bachelor of Science, Economics, Oguz, Integrity, International Drug Policy Consortium, Master of Science, Clinical research, Richard Roberts (pharmaceutical executive), Cancer Drugs Fund, Pharmacy school, School, Consumer, Phoenix International Holdings, Health technology assessment, Fine chemical, Pharmaceutical industry, Pharmacy

BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.

Key Points: 
  • BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.
  • This follows 7 years at a specialist economic consulting firm working in a small dedicated health and pharmaceutical team.
  • She regularly writes on hot topics affecting the industry for Pharmaceutical Executive, Pharmaphorum and EyeforPharma and has also written for PharmaTimes, and Pharma Pricing and Reimbursement.
  • She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry.

Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors

Retrieved on: 
Monday, December 5, 2022
Roche, Artificial intelligence, Drug discovery, Oncology, Business, FDA, University of Pittsburgh School of Medicine, Foundation Medicine, Probability, Doctor of Philosophy, Notre Dame, Advisory board, Patient, Wilfrid Sellars, Corporation, Medication, AI, University, Richard Roberts (pharmaceutical executive), Management, Pharmaceutical industry, Gritstone

EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., ( www.predictive-oncology.com ) to its Board of Directors to help support the company’s strategic initiatives and commercialization efforts.

Key Points: 
  • EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., ( www.predictive-oncology.com ) to its Board of Directors to help support the company’s strategic initiatives and commercialization efforts.
  • Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (Nasdaq: GRTS).
  • In addition to his Board role with Predictive Oncology, Dr. Hawryluk serves as an Advisory Board Member of PathAI, Inc.
    “People often talk about developing a strategy for a company to succeed, but it is so much more than that.
  • “Predictive Oncology has a forward-thinking plan; it has a bold vision and it has a sound strategy.

Pharmaceutical Executive® Opens Nominations for 2022 Emerging Pharma Leaders Awards Recognition Program

Retrieved on: 
Wednesday, January 26, 2022
Marketing, Industry, News, Medication, Richard Roberts (pharmaceutical executive), Pleasure, CEO, Fine chemical

CRANBURY, N.J., Jan. 26, 2022 /PRNewswire/ -- Pharmaceutical Executive ,a multimedia platform for industry leaders to exchange experiences and insights about innovative business and marketing ideas, is pleased to announce that nominations are now being accepted for the2022 Emerging Pharma Leadersawards recognition program, until February 25, 2022.

Key Points: 
  • CRANBURY, N.J., Jan. 26, 2022 /PRNewswire/ -- Pharmaceutical Executive ,a multimedia platform for industry leaders to exchange experiences and insights about innovative business and marketing ideas, is pleased to announce that nominations are now being accepted for the2022 Emerging Pharma Leadersawards recognition program, until February 25, 2022.
  • "Each year, we are consistently impressed by nominations we receive for the Emerging Pharma Leaders awards program," said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of Pharmaceutical Executive.
  • The Emerging Pharma Leaders awards recognition program was established in 2008 to recognize a select group of industry executives whose peers and supervisors believe will change the future of the pharma industry.
  • All eligible nominees employed by pharmaceutical or biotech companies will be judged by threePharmaceutical Executiveeditorial advisory board members and a former Emerging Pharma Leader representative.

Pharmaceutical Executive® Opens Call for Entries for Second Annual APEX Awards

Retrieved on: 
Thursday, January 13, 2022
Nursing, News, Medication, Industry, Marketing, Program, CEO, Richard Roberts (pharmaceutical executive), Pharmaceutical industry

CRANBURY, N.J., Jan. 13, 2022 /PRNewswire/ --Pharmaceutical Executive, a leading multimedia platform for industry leaders to exchange experiences and insights about innovative business and marketing ideas, today announced its call for entries for its second annual Pharmaceutical Executive APEX Awards .

Key Points: 
  • CRANBURY, N.J., Jan. 13, 2022 /PRNewswire/ --Pharmaceutical Executive, a leading multimedia platform for industry leaders to exchange experiences and insights about innovative business and marketing ideas, today announced its call for entries for its second annual Pharmaceutical Executive APEX Awards .
  • The annual medical advertising awards show celebrates the best creative health care work in the pharmaceutical industry.
  • "It is my pleasure to announce the opening of entries for the second annual Pharmaceutical ExecutiveAPEX Awards program," said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of Pharmaceutical Executive.
  • The Pharmaceutical Executive APEX Awards call-for-entry period runs from January 3 to March 18, 2022, with escalating prices across four entry periods.

Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology

Retrieved on: 
Wednesday, December 15, 2021
Leonardo S.p.A., San Francisco Bay Area, Nerve growth factor, Acquisition, NASDAQ, Inflammation, Oceana, Salix Pharmaceuticals, Takeda, CMC, FDA, Massachusetts Institute of Technology, Intelligence, Duane syndrome, IND, Perrigo, Drug development, Transplant, GLOBE, Partnership, U.S. FDA, Aramis, Bausch Health, Shire (pharmaceutical company), Harvard University, Science, K.V.N. Naik S.P. Sanstha's Polytechnic, CEO, Research, ISCB Senior Scientist Award, Associate, Ear, Regeneration, Schepens Eye Research Institute, Royal College of Surgeons, Immunology, New Drug Application, Endo International, Élan, University, Harvard Medical School, Royal college, Technology transfer, Richard Roberts (pharmaceutical executive), Patient, Leadership, Department, COO, Technology, Pharmaceutical industry, Ophthalmology

BOSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in ophthalmic pharmaceuticals. Proceeds from the financing will be used to advance the company’s pipeline, including its lead product candidate, A197, a novel, first-in-class, topical immunomodulatory agent licensed from Dompé farmaceutici, through Phase II clinical proof of concept for the treatment of dry eye disease.

Key Points: 
  • Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation and immunology, Reza Dana, M.D., M.P.H., M.Sc.
  • Aramis Biosciences was founded to address this treatment gap with A197, a new molecular entity promising a rapid onset of action, a durable, disease-modifying effect and a clean tolerability profile, said Reza Dana, M.D., M.P.H., M.Sc., Scientific Co-Founder of Aramis Biosciences.
  • Through its exclusive global license agreement, Aramis Biosciences has secured from Domp the global ophthalmic rights to this novel, first-in-class, topical immunomodulatory agent.
  • Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company committed to the development of disease-modifying therapy for ocular surface disease.

Pharmaceutical Executive® APEX Awards Announces 2021 Winners

Retrieved on: 
Tuesday, September 14, 2021
Marketing, Industry, Richard Roberts (pharmaceutical executive), CEO, Sun Pharma, Medication, Pharmaceutical industry

CRANBURY, N.J., Sept. 14, 2021 /PRNewswire/ -- Pharmaceutical Executive , aleadingmultimedia platform that exchanges experiences and insights about innovative business and marketing ideas, is pleased to announce the winners of the first annual, Pharmaceutical Executive2021 APEX Awards.

Key Points: 
  • CRANBURY, N.J., Sept. 14, 2021 /PRNewswire/ -- Pharmaceutical Executive , aleadingmultimedia platform that exchanges experiences and insights about innovative business and marketing ideas, is pleased to announce the winners of the first annual, Pharmaceutical Executive2021 APEX Awards.
  • Selected by an exceptional jury, compromised of the most respected and experienced health care professionals located across the United States, the winners exemplify the best creative health care work within the industry.
  • "Congratulations to the recipients of the first ever, Pharmaceutical Executive 2021 APEX Awards," said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of Pharmaceutical Executive.
  • This year's winners by award category are as follows:
    CDMP - Sun Pharmaceutical Industries, Ltd.